Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 and R^2 independently represent halogen, hydroxy, cyano, nitro, oxo, haloC_{1-6} alkyl, polyhaloC_{1-6} alkyl, haloC_{1-6} alkoxy, polyhaloC_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkoxy, arylC_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxyC_{1-6} alkyl, C_{3-7} cycloalkylC_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, aryl, heteroaryl, heterocyclyl <u>with 4-7 membered monocyclic saturated or partially unsaturated aliphatic ring containing 1 to 3 heteroatoms selected from oxygen or nitrogen</u>, arylC_{1-6} alkyl, heteroarylC_{1-6} alkyl, heterocyclylC_{1-6} alkyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonylC_{1-6} alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-6} alkyl, aryloxy, -CO-aryl, -CO-heterocyclyl, -CO-heteroaryl, C_{1-6} alkylsulfonamidoC_{1-6} alkyl, C_{1-6} alkylamidoC_{1-6} alkyl, arylsulfonamido, arylaminosulfonyl, arylsulfonamidoC_{1-6} alkyl, arylcarboxamidoC_{1-6} alkyl, aroylC_{1-6} alkyl, arylC_{1-6} alkanoyl, or a group $NR^{15}R^{16}$, $-NR^{15}$CO-aryl, $-NR^{15}$CO-heterocyclyl, $-NR^{15}$CO-heteroaryl, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-NR^{15}SO_2R^{16}$ or $-SO_2NR^{15}R^{16}$, wherein R^{15} and R^{16} independently represent hydrogen or C_{1-6} alkyl;

wherein said aryl, heteroaryl and heterocyclyl groups of R^1 and R^2 may be optionally substituted by one or more substituents which may be the same or

different and which are selected from halogen, C_{1-6} alkyl, C_{1-6} alkoxy, oxo, CF_3, OCF_3, CN, C_{1-6} alkanoyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylamido or C_{1-6} alkylsulfonamido;

a and b independently represent 0, 1 or 2, such that a and b cannot both represent 0;

$=\!=$ is a single or double bond;

R^3 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl;

m and n independently represent 0, 1 or 2;

p represents an integer from 0 to 3, such that when p is an integer greater than 1, two R^1 groups may instead be linked to form a heterocyclyl group;

R^4 represents $-(CH_2)_q-NR^{11}R^{12}$ or a group of formula (i):



(i)

wherein q is 2, 3 or 4;

R^{11} and R^{12} independently represent C_{1-6} alkyl or together with the nitrogen atom to which they are attached represent an N-linked heterocyclic group optionally substituted by one or two R^{17} groups;

R^{13} represents hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, $-C_{1-6}$ alkyl-aryl or heterocyclyl;

R^{14} and R^{17} independently represent halogen, C_{1-6} alkyl, haloC_{1-6} alkyl, OH, diC_{1-6} alkylamino or C_{1-6} alkoxy;

f and k independently represent 0, 1 or 2;

g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0;

or solvates thereof.

2. (Original) A compound as defined in claim 1 wherein R^1 represents halogen, hydroxy, cyano, nitro, $-NR^{15}R^{16}$, $-NR^{15}COR^{16}$, polyhaloC_{1-6} alkyl, heterocyclyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6}

alkanoyl, arylsulfonamido, arylaminosulfonyl, $-NR^{15}SO_2R^{16}$, $-SO_2NR^{15}R^{16}$, –CO-heterocyclyl or two R^1 groups are linked to form a heterocyclyl group.

3. (Original) A compound as defined in claim 2 wherein p represents 1 and R^1 represents fluoro or cyano.

4. (Currently Cancelled)

5. (Previously Amended) A compound as defined in claim 1 wherein m represents 1 and R^2 represents C_{1-6} alkyl, arylC_{1-6} alkyl, aryl or heteroaryl.

6. (Currently Cancelled).

7. (Previously Amended) A compound as defined in claim 1 wherein n represents 1 and R^3 represents halogen or polyhaloC_{1-6} alkyl.

8.-11 (Currently Cancelled).

12. (Previously Amended) A compound as defined in claim 1 wherein R^4 represents $-(CH_2)_q-NR^{11}R^{12}$, q represents 3 and $NR^{11}R^{12}$ represents unsubstituted piperidine.

13. (Currently Cancelled).

14. (Previously Amended) A compound according to claim 1 which is selected from the group consisting of:
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]indoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-3,4-dihydro-1H-isoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-bromoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]indole;
5-Fluoro-2-methyl-N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-indole;

5-Methoxy-2-methyl-N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-indole;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-fluoroindoline;

($\pm$)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-2-methylindoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1,2,3,4-tetrahydroquinoline;

N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-nitroisoindoline;

N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-aminoisoindoline;

N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-(1-succinimido)-isoindoline;

N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-(2-oxo-pyrrolidin-1-yl)-isoindoline;

N-[4-(3-Piperidin-1-ylpropoxy)-2-trifluoromethyl-benzoyl]isoindoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6-cyano-1,2,3,4-tetrahydroisoquinoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-cyano-1,2,3,4-tetrahydroisoquinoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-methylsulfonyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-3,3-dimethylindoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-methoxy-6-trifluoromethyl-indoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-(dimethylaminosulfonyl)-indoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-(methylsulfinyl)-indoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-(methylsulfonyl)-indoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-acetyl-indoline;

($\pm$)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-2-methyl-1,2,3,4-tetrahydroquinoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6-methyl-1,2,3,4-tetrahydroquinoline;

($\pm$)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-benzyl-1,2,3,4-tetrahydroisoquinoline;

($\pm$)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-(phenylsulfonamido)-1,2,3,4-tetrahydroisoquinoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-(phenylaminosulfonyl)-1,2,3,4-tetrahydroisoquinoline;

(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-1,2,3,4-tetrahydroisoquinoline;

N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-methoxyisoindoline;

N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-trifluoromethylisoindoline;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-acetyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-acetylamino-8-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-methylsulfonamido-8-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]- 6,7,8,9-tetrahydro-5*H*-[1,3]dioxolo[4,5-*h*][3]benzazepine;

(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-6,7-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-8,9-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-7,9-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-7-hydroxy-8-methylsulfonyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-(4-methoxyphenyl)-6,9-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-thienyl-7,8-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6-bromo-7,8-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

($\pm$)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-(4-i-propylsulfonyl)-6-chloro-7,8-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-fluoro-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6-chloro-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7,8-dichloro-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-8-chloro-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-cyano-2,3,4,5-tetrahydro-1*H*-3-benzazepine;N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-4-fluoroisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-cyanoisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-[(pyrrolidin-1-yl)carbonyl]isoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-[(morpholin-4-yl)carbonyl]isoindoline;
N-[2-Chloro-4-(3-Piperidin-1-ylpropoxy)benzoyl]isoindoline;
N-{2-Chloro-4-[(1-isopropyl-4-piperidinyl)oxy]benzoyl}isoindoline;
N-{2-Chloro-4-[(1-isopropyl-4-piperidinyl)oxy]benzoyl}-5-fluoro-isoindoline;
N-{2-Chloro-4-[(1-cyclobutyl-4-piperidinyl)oxy]benzoyl}isoindoline; or
N-{2-Chloro-4-[(1-cyclobutyl-4-piperidinyl)oxy]benzoyl}-5-fluoro-isoindoline
or a pharmaceutically acceptable salt thereof.

15. (Previously Amended) A compound according to claim 1 which is selected from the group consisting of:
N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-fluoroisoindoline;
N-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]benzoyl}isoindoline; or
N-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]benzoyl}-5-fluoro-isoindoline
or a pharmaceutically acceptable salt thereof.

16. (Original) A compound according to claim 1 which is N-[4-(3-piperidin-1-ylpropoxy)benzoyl]isoindoline or a pharmaceutically acceptable salt thereof.

17. (Previously Amended) A pharmaceutical composition which comprises the compound of formula (I) as defined in claim 1 or a

pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

18.-22. (Currently Cancelled).

23. (Currently Amended) A process for the preparation of a compound of ~~formula (I)~~ claim 1 or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II)



(II)

with a compound of formula (III)



(III)

or a protected derivative thereof, wherein R^1, R^2, R^3, R^4, a, b, m, n and p are as defined in claim 1 and L is OH or a suitable leaving group; or

(b) preparing a compound of ~~formula (I)~~ claim 1 wherein R^4 represents -$(CH_2)_q$-$NR^{11}R^{12}$ which comprises reacting a compound of formula (IV)



(IV)

wherein R^1, R^2, R^3, a, b, m, n, p and q are as defined in claim 1 and L^1 represents a suitable leaving group with a compound of formula $HNR^{11}R^{12}$; wherein R^{11} and R^{12} are as defined in claim 1; and optionally thereafter

(c) deprotecting a compound of ~~formula (I)~~ claim 1 which is protected; and optionally thereafter

(d) interconversion to other compounds of ~~formula (I)~~ claim 1.